Advanced Biomed Inc. (ADVB)
NASDAQ: ADVB · Real-Time Price · USD
0.2131
-0.0255 (-10.69%)
At close: Feb 18, 2026, 4:00 PM EST
0.2250
+0.0119 (5.58%)
After-hours: Feb 18, 2026, 7:59 PM EST
Advanced Biomed Employees
Advanced Biomed had 31 employees as of June 30, 2025. The number of employees decreased by 9 or -22.50% compared to the previous year.
Employees
31
Change
-9
Growth
-22.50%
Revenue / Employee
n/a
Profits / Employee
$141,469
Market Cap
5.82M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 31 | -9 | -22.50% |
| Sep 30, 2024 | 40 | 0 | - |
| Jun 30, 2024 | 40 | 0 | - |
| Dec 31, 2023 | 40 | - | - |
| Sep 30, 2023 | 40 | 2 | 5.26% |
| Jun 30, 2023 | 40 | 2 | 5.26% |
| Jun 30, 2022 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Inotiv | 2,046 |
| FONAR | 535 |
| XWELL | 312 |
| Biodesix | 273 |
| Exagen | 215 |
| Precipio | 60 |
| bioAffinity Technologies | 57 |
| Mainz Biomed | 26 |
ADVB News
- 14 hours ago - Advanced Biomed Inc. Announces 1 for 20 Share Consolidation - GlobeNewsWire
- 5 days ago - Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery - GlobeNewsWire
- 7 weeks ago - Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary - GlobeNewsWire
- 5 months ago - Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery - GlobeNewsWire
- 10 months ago - Sonoro Energy, Advanced BioCatalytics, and NexTier Energy Launch Strategic Collaboration to Advance Heavy Oil Recovery from Carbonate Reservoirs in the Middle East - TheNewswire
- 1 year ago - Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering - GlobeNewsWire
- 2 years ago - IPO Update: Advanced Biomed Finalizes $112 Million U.S. IPO Plan - Seeking Alpha
- 2 years ago - Advanced Biomed sets IPO terms, which could value the biotech at up to $625 million - Market Watch